Informa Australia is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Find Topic

Healthcare

Pfizer to acquire King Pharmaceuticals for $3.6 billion.

Expert comment from Datamonitor principal analyst Simon King: “The King acquisition represents a small but integral part of a broader diversification strategy that continues to be implemented by Pfizer. This strategy has to date encompassed the multi-billion dollar acquisition of Wyeth but also various in-licensing agreements and a concerted movement into the generics market as…

15 Oct 2010, by Informa Insights

Healthcare

The case for constant innovation in Australian biotech

Melbourne – 12th October 2010 – The sales contribution from internally developed products is expected to decline from $284 billion in 2009 to $274 billion in 2014, by which time the majority of sales will be derived from externally sourced products. Pharma’s continued need to restock pipelines in order to secure future growth—in the face…

12 Oct 2010, by Informa Insights

Healthcare

Asia-Pacific products are in later stages of development compared to other markets

Melbourne – 11th October 2010 – Asia-Pacific products are in later stages of development compared to other markets, but still comprise only 15% of global products in development according to MedTRACK, a market leading database of private and public biomedical companies. The volume of products in development in the Asia-Pacific region still lags behind North…

11 Oct 2010, by Informa Insights

Healthcare

Implications of Nivestim’s approval on the Australian biosimilars market

Melbourne – 6th October 2010 – Biosimilars in Australia: Nivestim approval opens up local filgrastim biosimilars market. Lisette Oversteegen, Lead Analyst, comments: “Although the recent approval of biosimilar filgrastim is a positive development for the Australian industry, the proposed biosimilars pricing regulations may slow uptake”. Compared with Europe, where several biosimilar products of three different…

6 Oct 2010, by Informa Insights

Healthcare

The Australian reimbursement committee is set to consider Novo Nordisk’s type 2 diabetes treatment

Melbourne – 5th October 2010 - Novo Nordisk: swift approval of Victoza for reimbursement is vital to the drug's success. Lisette Oversteegen, Lead Analyst, comments: “For a prescription drug to be commercially successful in Australia, being included on the country's government reimbursement list, the Pharmaceutical Benefits Scheme (PBS) is essential”. In its November meeting, the…

5 Oct 2010, by Informa Insights

Healthcare

Biologic treatments for rheumatoid arthritis to capture greater market share

[tweetmeme source= "informa_oz" only_single=false] Melbourne, 30th September 2010 - Use of biologic disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis is set to increase dramatically over the next five years finds independent market analyst, Datamonitor. Despite their considerable cost, rheumatologists interviewed by Datamonitor in the US, Europe and Japan expect a continued increase…

30 Sep 2010, by Informa Insights

Healthcare

Venture Financing in Asia-Pacific looks promising

[tweetmeme source= "informa_oz" only_single=false] Melbourne – 28th September 2010 – MedTRACK, a market leading database of private and public biomedical companies, reports that the number of transactions in the Asia-Pacific region is on pace to rebound by 15% in 2010. Sarah Terry, President of MedTRACK comments: To be a company in Asia-Pacific region is really…

28 Sep 2010, by Informa Insights

Healthcare

Antidyslipidemics | End of an Era

[tweetmeme source= "informa_oz" only_single=false] The domination of the antidyslipidemic market by five top brands is set to fundamentally change over the next 10 years as novel agents fail to meet the success of their predecessors, claims a new report from independent market analyst, Datamonitor. The top five antidyslipidemic brands: Lipitor (atorvastatin, Pfizer), Crestor (rosuvastatin, AstraZeneca),…

28 Sep 2010, by Informa Insights

Healthcare

Cancer Targeted Therapies and Immunotherapies | Resisting Competitive Pressures

[tweetmeme source= "informa_oz" only_single=false] Drug developers aiming to emulate the success of cancer targeted therapies and immunotherapy brands will struggle as a result of heightened competition and pharmacoeconomic constraints, suggests independent market analyst, Datamonitor. Over the last decade the targeted therapies and immunotherapies class has fuelled growth in the oncology market, making it very attractive…

28 Sep 2010, by Informa Insights

Healthcare

J&J in Talks to Buy Crucell | Expert Analyst Comment

[tweetmeme source= "informa_oz" only_single=false] Johnson & Johnson is in advanced negotiations to buy Dutch biotechnology company Crucell NV for €1.75 billion ($2.29 billion), the two companies said today. Giles Somers, senior healthcare analyst at Datamonitor comments: “So, one more big Pharma enters the vaccines space – following the example of Pfizer (through the acquisition of…

28 Sep 2010, by Informa Insights
Page  of 44

Get all the latest on Informa news and events

Informa Connect Australia is the nation's leading event organiser. Our events comprise of large scale exhibitions, industry conferences and highly specialised corporate training.

Find out more

Subscribe to Insights
SUBSCRIBE 

Join Our Newsletter
Informa Insights

Stay up-to-date with all the latest
updates, upcoming events & more.
close-link
COVID-19  Cancellation  Policy
Read  Policy  Terms
close-image